R R

What Is Nivolumab-Related Ocular Inflammation?

Nivolumab–related ocular inflammation refers to eye inflammation that develops as an immune–related adverse effect of the cancer drug nivolumab. Nivolumab is a PD–1 checkpoint inhibitor used to treat several malignancies, including melanoma and lung cancer. By boosting the immune response against tumors, it can also trigger unintended inflammation in normal tissues. In the eye, this can present as uveitis, scleritis, dry eye, or orbital inflammation. Early recognition helps protect vision while allowing cancer therapy to continue when possible.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Nivolumab-Related Ocular Inflammation?

Nivolumab–related ocular inflammation refers to eye inflammation that develops as an immune–related adverse effect of the cancer drug nivolumab. Nivolumab is a PD–1 checkpoint inhibitor used to treat several malignancies, including melanoma and lung cancer. By boosting the immune response against tumors, it can also trigger unintended inflammation in normal tissues. In the eye, this can present as uveitis, scleritis, dry eye, or orbital inflammation. Early recognition helps protect vision while allowing cancer therapy to continue when possible.

read more about nivolumabrelated ocular inflammation ...

Copy this HTML:

Copy HTML Copied!

Types of Ocular Involvement

Nivolumab–related eye problems most often include anterior or intermediate uveitis with redness, pain, and photophobia. Some patients develop panuveitis, choroiditis, or optic nerve inflammation. Dry eye from lacrimal gland dysfunction and inflammatory scleritis or episcleritis are also reported. Symptoms usually arise weeks to months after starting treatment but can appear later in the course. The pattern can mimic autoimmune uveitis, and both eyes are frequently involved, though sometimes asymmetrically.

Symptoms and Clinical Findings

Patients may report blurred vision, new floaters, light sensitivity, eye pain, or a gritty sensation. On slit lamp examination, clinicians can see anterior chamber cells and flare, keratic precipitates, ciliary injection, or scleral tenderness. Fundus examination may show vitreous cells, retinal vasculitis, choroidal lesions, or optic disc edema. In milder cases, findings are limited to surface dryness and punctate epithelial staining. Documenting the onset relative to nivolumab dosing is an important clinical clue.

Diagnosis and Workup

Diagnosis is based on linking new ocular inflammation with recent or ongoing nivolumab therapy while excluding infections and other autoimmune causes. The clinician takes a detailed oncologic and medication history and reviews other immune–related adverse events such as colitis, dermatitis, or arthritis. Laboratory tests and imaging are tailored to rule out masquerade syndromes and opportunistic infections, especially in immunocompromised hosts. Close communication with the oncology team is essential when deciding whether to pause, continue, or adjust cancer treatment.

Management and Prognosis

Treatment usually involves topical corticosteroid drops and cycloplegics for anterior uveitis, with periocular or systemic steroids used for more extensive disease. In some cases, nivolumab is held or discontinued if inflammation is severe or sight threatening. Steroid–sparing immunomodulatory therapy can be considered when cancer control requires ongoing checkpoint inhibition. Many patients improve with appropriate treatment, though recurrent or chronic inflammation can occur. Regular follow up monitors both ocular status and systemic cancer care.

FAQs About Nivolumab-Related Ocular Inflammation

Can nivolumab cause permanent eye damage?

Serious damage is possible if aggressive uveitis or optic nerve involvement is not treated promptly, but many cases improve with steroids and careful management.

Do all patients on nivolumab get eye inflammation?

No, ocular events are relatively uncommon compared with other immune–related side effects.

Should nivolumab be stopped if eye inflammation occurs?

The decision is individualized and made jointly by oncology and eye specialists, depending on severity and cancer status.

Will my vision return to normal after treatment?

Many patients recover good vision, especially when inflammation is detected early and treated promptly, though some can have residual changes.

References

FDA. ?OPDIVO (nivolumab) Injection Label.? https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s112lbl.pdf

European Medicines Agency (EMA). ?Opdivo, INN-nivolumab (EPAR Product Information).? https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf

EyeWiki. ?Ocular and Orbital Complications of Checkpoint Inhibitors.? https://eyewiki.org/Ocular_and_Orbital_Complications_of_Checkpoint_Inhibitors

American Academy of Ophthalmology (AAO). ?Checkpoint inhibitors may lead to uveitis and other ocular adverse events.? https://www.aao.org/education/editors-choice/checkpoint-inhibitors-may-lead-to-uveitis-other-in

NCBI (PMC). ?Bilateral uveitis associated with nivolumab therapy for metastatic melanoma.? https://pmc.ncbi.nlm.nih.gov/articles/PMC5514288/